Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: Final results

Authors

Abdulraheem Yacoub, University of Kansas
Stephen T Oh, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

3-26-2024

Volume

8

Issue

6

First Page

1515

Last Page

1528

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2023011620

Rights and Permissions

Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs G, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh ST, Schiller G, McCloskey J, Palmer J, Holmes H, Hager S, Assad A, Erickson-Viitanen S, Zhou F, Daver N. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024 Mar 26;8(6):1515-1528. doi: 10.1182/bloodadvances.2023011620. © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Yacoub, Abdulraheem; Oh, Stephen T; and et al., "Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: Final results." Blood Advances. 8, 6. 1515 - 1528. (2024).
https://digitalcommons.wustl.edu/oa_4/3512

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.